{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T08:46:05Z","timestamp":1744965965988,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11255-019-02292-1","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T13:11:19Z","timestamp":1570021879000},"page":"2015-2025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis"],"prefix":"10.1007","volume":"51","author":[{"given":"Chun-Hung","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-7986","authenticated-orcid":false,"given":"Chia-Ter","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Cheng","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsu-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai-Szu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"2292_CR1","first-page":"477","volume":"79","author":"F Davies","year":"1991","unstructured":"Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D (1991) Polycystic kidney disease re-evaluated: a population-based study. Q J Med 79:477\u2013485","journal-title":"Q J Med"},{"key":"2292_CR2","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S et al (2016) Mutations in GANAB, encoding the glucosidase Iialpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193\u20131207","journal-title":"Am J Hum Genet"},{"key":"2292_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrneph.2017.127","volume":"13","author":"MB Lanktree","year":"2017","unstructured":"Lanktree MB, Chapman AB (2017) New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol 13:750\u2013768","journal-title":"Nat Rev Nephrol"},{"key":"2292_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneph.2014.104","volume":"10","author":"N Kanaan","year":"2014","unstructured":"Kanaan N, Devuyst O, Pirson Y (2014) Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 10:455\u2013465","journal-title":"Nat Rev Nephrol"},{"key":"2292_CR5","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.transproceed.2018.02.100","volume":"50","author":"M Jankowska","year":"2018","unstructured":"Jankowska M, Kuzmiuk-Glembin I, Skonieczny P, Debska-Slizien A (2018) Native nephrectomy in renal transplant recipients with autosomal dominant polycystic kidney disease. Transplant Proc 50:1863\u20131867","journal-title":"Transplant Proc"},{"key":"2292_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJM199307293290508","volume":"329","author":"PA Gabow","year":"1993","unstructured":"Gabow PA (1993) Autosomal dominant polycystic kidney disease. N Engl J Med 329:332\u2013342","journal-title":"N Engl J Med"},{"key":"2292_CR7","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G (2015) Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385:1993\u20132002","journal-title":"Lancet"},{"key":"2292_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.2011040340","volume":"23","author":"Z Novalic","year":"2012","unstructured":"Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ (2012) Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 23:842\u2013853","journal-title":"J Am Soc Nephrol"},{"key":"2292_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000104818","volume":"30","author":"M Wu","year":"2007","unstructured":"Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL (2007) Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30:253\u2013259","journal-title":"Kidney Blood Press Res"},{"key":"2292_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:479\u2013486","journal-title":"Clin J Am Soc Nephrol"},{"key":"2292_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/nep.12211","volume":"19","author":"TM Myint","year":"2014","unstructured":"Myint TM, Rangan GK, Webster AC (2014) Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials. Nephrology 19:217\u2013226","journal-title":"Nephrology"},{"key":"2292_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000354398","volume":"124","author":"C Xue","year":"2013","unstructured":"Xue C, Dai B, Mei C (2013) Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis. Nephron Clin Pract 124:10\u201316","journal-title":"Nephron Clin Pract"},{"key":"2292_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2215\/CJN.02650313","volume":"9","author":"WE Braun","year":"2014","unstructured":"Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR (2014) Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol 9:881\u2013888","journal-title":"Clin J Am Soc Nephrol"},{"key":"2292_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","volume":"59","author":"M Chrispijn","year":"2013","unstructured":"Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP (2013) Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 59:153\u2013159","journal-title":"J Hepatol"},{"key":"2292_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.09900915","volume":"11","author":"P Ruggenenti","year":"2016","unstructured":"Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G (2016) Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin J Am Soc Nephrol 11:785\u2013794","journal-title":"Clin J Am Soc Nephrol"},{"key":"2292_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1681\/ASN.2009121302","volume":"21","author":"N Perico","year":"2010","unstructured":"Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Enelordache B, Remuzzi A, Remuzzi G (2010) Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21:1031\u20131040","journal-title":"J Am Soc Nephrol"},{"key":"2292_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820\u2013829","journal-title":"N Engl J Med"},{"key":"2292_CR18","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.transproceed.2012.06.073","volume":"44","author":"A Soliman","year":"2012","unstructured":"Soliman A, Zamil S, Lofty A, Ismail E (2012) Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment. Transplant Proc 44:2936\u20132939","journal-title":"Transplant Proc"},{"key":"2292_CR19","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","volume":"27","author":"G Stallone","year":"2012","unstructured":"Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L (2012) Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant 27:3560\u20133567","journal-title":"Nephrol Dial Transplant"},{"key":"2292_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830\u2013840","journal-title":"N Engl J Med"},{"key":"2292_CR21","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1093\/ndt\/gfp280","volume":"24","author":"AL Serra","year":"2009","unstructured":"Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wuthrich RP (2009) Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 24:3334\u20133342","journal-title":"Nephrol Dial Transplant"},{"key":"2292_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40264-019-00810-9","volume":"42","author":"LS Nguyen","year":"2019","unstructured":"Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem J-E (2019) Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf 42:813\u2013825","journal-title":"Drug Saf"},{"key":"2292_CR23","first-page":"CD010294","volume":"7","author":"D Bolignano","year":"2015","unstructured":"Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF (2015) Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev 7:CD010294","journal-title":"Cochrane Database Syst Rev"},{"key":"2292_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10157-016-1289-1","volume":"21","author":"L de Stephanis","year":"2017","unstructured":"de Stephanis L, Bonon A, Varani K, Lanza G, Gafa R, Pinton P, Pema M, Somlo S, Boletta A, Aguiari G (2017) Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells. Clin Exp Nephrol 21:203\u2013211","journal-title":"Clin Exp Nephrol"},{"key":"2292_CR25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1172\/JCI72272","volume":"124","author":"PC Harris","year":"2014","unstructured":"Harris PC, Torres VE (2014) Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124:2315\u20132324","journal-title":"J Clin Invest"},{"key":"2292_CR26","first-page":"1356","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS (2017) Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant 32:1356\u20131363","journal-title":"Nephrol Dial Transplant"},{"key":"2292_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.molmed.2014.01.004","volume":"20","author":"SV Fedeles","year":"2014","unstructured":"Fedeles SV, Gallagher AR, Somlo S (2014) Polycystin-1: a master regulator of intersecting cystic pathways. Trend Mol Med 20:251\u2013260","journal-title":"Trend Mol Med"},{"key":"2292_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrneph.2013.73","volume":"9","author":"TJ Watnick","year":"2013","unstructured":"Watnick TJ, Germino GG (2013) Polycystic kidney disease: polycystin-1 and polycystin-2\u2014it\u2019s complicated. Nat Rev Nephrol 9:249\u2013250","journal-title":"Nat Rev Nephrol"},{"key":"2292_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ki.2015.207","volume":"88","author":"AC Ong","year":"2015","unstructured":"Ong AC, Harris PC (2015) A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney Int 88:699\u2013710","journal-title":"Kidney Int"},{"key":"2292_CR30","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2215\/CJN.01360210","volume":"5","author":"VE Torres","year":"2010","unstructured":"Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wuthrich RP (2010) Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 5:1312\u20131329","journal-title":"Clin J Am Soc Nephrol"},{"key":"2292_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1172\/JCI28984","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ (2007) PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR. J Clin Invest 117:730\u2013738","journal-title":"J Clin Invest"},{"key":"2292_CR32","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/jcmm.13091","volume":"21","author":"A Li","year":"2017","unstructured":"Li A, Fan S, Xu Y, Meng J, Shen X, Mao J, Zhang L, Zhang X, Moeckel G, Wu D, Wu G, Liang C (2017) Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis. J Cell Mol Med 21:1619\u20131635","journal-title":"J Cell Mol Med"},{"key":"2292_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1681\/ASN.2007050626","volume":"19","author":"Q Qian","year":"2008","unstructured":"Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE (2008) Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19:631\u2013638","journal-title":"J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02292-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T23:23:48Z","timestamp":1601421828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2292"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02292-1","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no relevant financial or non-financial competing interests to declare in relation to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}